Correlation Engine 2.0
Clear Search sequence regions

  • angiogenesis (1)
  • eczema (1)
  • haemangioma (4)
  • humans (1)
  • kaposi sarcoma (1)
  • receptor (1)
  • rosacea (1)
  • timolol (5)
  • wound (3)
  • Sizes of these terms reflect their relevance to your search.

    Timolol, a nonselective β-adrenergic receptor blocker, is well-tolerated and is becoming increasingly popular in dermatology, especially in the management of infantile haemangioma (IH). Its effects are mainly due to vasoconstriction, inhibition of angiogenesis and keratinocyte migration promotion for re-epithelialization and wound healing. We review the evidence behind the use of timolol in several dermatological conditions including IH, pyogenic granulomas, Kaposi sarcoma, chronic wound healing, postsurgical wounds, acne vulgaris, rosacea, eczema and red scrotum syndrome. © 2021 British Association of Dermatologists.


    M Alzaid, A Al-Naseem, F Al-Niaimi, F R Ali. Topical timolol in dermatology: infantile haemangiomas and beyond. Clinical and experimental dermatology. 2022 May;47(5):819-832

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 34798680

    View Full Text